Torrent Pharma profit slips despite robust revenue surge in Q2

Torrent Pharmaceuticals' second-quarter results underscore the challenges facing India's pharmaceutical sector, with the company posting a contraction in profitability despite strong topline growth. Net profit for Q2FY27 fell to ₹534 crore from the previous year's levels, marking a 9.6% year-on-year decline.

The decline came despite revenue surging 50.8%, reflecting a significant expansion in the company's sales footprint and market reach. However, the growth in the top line failed to translate into proportional profit expansion, as operational pressures mounted.

Higher finance costs and increased depreciation charges were the primary drags on earnings during the quarter. The elevated finance costs likely reflect the company's debt servicing obligations, while depreciation increases suggest continued capital investment in infrastructure and manufacturing capacity.

The results highlight a broader trend in India's pharma sector where companies are prioritising revenue growth and market expansion over near-term profitability. Torrent's performance indicates that while the company is successfully scaling its business, it faces pressure from rising operational and financial expenses that are constraining margin expansion in the short term.